


Supplemental Data

**Marketed Drugs Can Inhibit Cytochrome P450 27A1 (CYP27A1), a Potential New Target  
for Breast Cancer Adjuvant Therapy**

Natalia Mast, Joseph B. Lin, and Irina A. Pikuleva

Molecular Pharmacology

**Supplemental Figure 1.** The studied (in bold) and other activities of CYP27A1.



**Supplemental Table 1.** FDA-approved anti-cancer drugs and some of non-cancer drugs. Drugs that were excluded from screening are in gray and those that were tested are in black and underlined.

<b>FDA-Approved Anti-Cancer Drugs (116)</b>		<b>Non-Cancer Drugs</b>	
<b>Bulky (38)</b>		<b>Absorbing in visible region (2)</b>	<b>Inhibitors of CYPs 46A1 and 11A1 (7)</b>
abiraterone	vandetanib	carmustine	<u>dexmedetomidine</u>
bleomycin	vemurafenib	methotrexate	<u>fluvoxamine</u>
cabazitaxel	vinblastine		<u>hexaconazole</u>
carfilzomib	<b>Peptide-based (22)</b>	<b>Containing hindered nitrogens (21)</b>	<u>posaconazole</u>
dabrafenib	alemtuzumab	afatinib	<u>ravuconazole</u>
dactinomycin	asparaginase	arsenic trioxide	<u>thioperamide</u>
daunorubicin	bevacizumab	bendamustine	<u>tranlycypromine</u>
degarelix	brentuximab vedotin	bexarotene	
docetaxel	cetuximab	busulfan	<b>Containing platinum (3)</b>
doxorubicin	denosumab	cabozantinib	carboplatin
enzalutamide	filgrastim	capecitabine	<u>cisplatin</u>
epirubicin	gemtuzumab ozogamicin	chlorambucil	oxaliplatin
erlotinib	glucarpidase	cyclophosphamide	
etoposide	ibrutumomab tiuxetan	dasatinib	<b>Anti-breast cancer aromatase inhibitors (5)</b>
everolimus	ipilimumab	eltrombopag	<u>aminoglutethimide</u>
fulvestrant	obinutuzumab	gefitinib	<u>anastrozole</u>
goserelin	ofatumumab	ibrutinib	<u>exemestane (steroid)</u>
ixabepilone	palifermin	ifosfamide	<u>fadrozole</u>
lapatinib	panitumumab	irinotecan	<u>letrozole</u>
leucovorin	pegaspargase	lomustine	
leuprolide	pertuzumab	mesna	
megestrol	rasburicase	palonosetron	
nilotinib	rituximab	sunitinib malate	
paclitaxel	romiplostim	tamoxifen	
pazopanib	tositumomab	toremifene	
plerixafor	trastuzumab emtansine		
ponatinib		<b>Nucleotide derivatives (6)</b>	
pralatrexate	<b>Cost prohibitive (7)</b>	<u>azacitidine</u>	
raloxifene	dexrazoxane	cytarabine	
romidepsin	lenalidomide	decitabine	
temsirolimus	mechlorethamine	fludarabine	
topotecan	pemetrexed	gemcitabine	
trametinib	regorafenib	nelarabine	
vincristine	ruxolitinib		
vinorelbine	thalidomide		
			<b>Others (12)</b>
			<u>aminolevulinic acid</u>
			<u>aprepitant</u>
			<u>axitinib</u>
			<u>bicalutamide</u>
			<u>clofarabine</u>
			<u>crizotinib</u>
			<u>dacarbazine</u>
			<u>imexon</u>
			<u>pamidronate</u>
			<u>procarbazine</u>
			<u>temozolomide</u>
			<u>vorinostat</u>